This brief overview of recently presented improvements in lung cancer therapy highlights the substantial benefits of newer chemotherapy and immunotherapy regimens that are transforming the outlooks of many patients with advanced lung cancer.
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Lung - Cancer
November 7, 2019
Incidence, Management, and Outcomes of Intraoperative Catastrophes During Robotic Pulmonary Resection
October 24, 2019
This multiinstitutional study including advocates of robotic lung resection identified a 1.9% incidence of intraoperative castrophes, most commonly pulmonary arterial bleeding. Patients at risk had lower FEV1%, higher clinical stage, and more frequent preoperative radiation therapy.
October 24, 2019
This analysis of data from the JCOG0201 trial identified factors that place patients at increased risk for recurrence after lobectomy for stage I adenocarcinoma. They include visceral pleural invasion, vascular invasion, or an invasive component measuring >2 cm.
October 21, 2019
Better cardiorespiratory fitness as quantified by treadmill exercise testing was associated with a substantially decreased likelihood of lung cancer in former smokers (77% reduction in very fit) and reduced mortality in smokers who subsequently developed lung cancer (85% reduction in very fit).
September 27, 2019
Interesting to see the long term curative results of this randomized controlled trial.
Prediction of Response to Anti-PD-1 Therapy in Patients With Non-small-cell Lung Cancer by Electronic Nose Analysis of Exhaled Breath
September 20, 2019
Immune checkpoint inhibitors have revolutionized treatment of non-small cell lung cancer. In this study, breath prophiles were collected from 143 patients and a single biomarker profile was created that detected responses to anti-PD-1 treatment with 89% accuracy.
August 22, 2019
This study of over 25,000 pts from the International Lung Cancer Consortium identified underweight and severly obese patients as having poorer survival than others, whereas a survival advantage was evident among patients who were overweight or mildly obese. Decreased BMI (wt loss) was associated with poorer outcomes across all BMI categories.
August 20, 2019
Interesting follow-up study of 208 pulmonary ground -glass opacities in 160 subjects, with a yield of three adenocardinomas.
Association of Discretionary Hospital Volume Standards for High-Risk Cancer Surgery With Patient Outcomes and Access, 2005-2016
August 15, 2019
Regionalization of care for complex problems remains an open question in most countries. This review demonstrated that, for high risk cancer operations in the US, the Leapfrog group's volume standards did not differentiate between surgical mortality outcomes for lung and esophageal cancer surgery.
August 8, 2019
A detailed and robust meta-analysis asserting lack of strong evidence supporting either modality.